Crude response and remission rates at 6 and 12 months among adalimumab, etanercept and infliximab users in those who were biologically naive
| 6 Months | 12 Months | |||||
|---|---|---|---|---|---|---|
| INF | ADA | ETA | INF | ADA | ETA | |
| mACR response | ||||||
| No of patients | 230 | 235 | 222 | 182 | 190 | 178 |
| mACR 20 | ||||||
| Responders (%) | 26.5 | 30.6 | 37.4 | 26.9 | 26.8 | 31.5 |
| Adjusted OR* | 1.00 | 0.95 (0.60–1.50) | 1.37 (0.94–1.99) | 1.00 | 0.96 (0.56, 1.64) | 1.35 (0.84, 2.18) |
| mACR50 | ||||||
| Responders (%) | 14.3 | 19.6 | 26.6 | 20.3 | 17.4 | 20.8 |
| Adjusted OR* | 1.00 | 1.03 (0.52, 2.01) | 1.75 (0.99, 3.09) | 1.00 | 0.72 (0.46–1.13) | 1.03 (0.62–1.70) |
| mACR70 | ||||||
| Responders (%) | 9.6 | 10.2 | 9.9 | 12.1 | 12.1 | 11.8 |
| Adjusted OR* | 1.00 | 0.76 (0.41–1.42) | 0.81 (0.42–1.56) | 1.00 | 0.83 (0.46–1.49) | 1.04 (0.61–1.78) |
| CDAI remission | ||||||
| No of patients | 254 | 249 | 242 | 199 | 202 | 189 |
| Responders (%) | 15.7 | 13.7 | 16.1 | 17.1 | 12.9 | 18.5 |
| Adjusted OR† | 1.00 | 0.83 (0.42–1.63) | 1.18 (0.65–2.14) | 1.00 | 0.69 (0.42–1.15) | 1.15 (0.61–2.12) |
| DAS28 remission | ||||||
| No of patients | 103 | 107 | 116 | 71 | 75 | 72 |
| Responders (%) | 28.2 | 25.2 | 28.4 | 33.8 | 33.3 | 37.5 |
| Adjusted OR† | 1.00 | 0.72 (0.48–1.08) | 0.95 (0.43–2.08) | 1.00 | 0.89 (0.39–2.00) | 1.01 (0.47–2.12) |
↵* Adjusted for duration of RA, joint counts, patient global, age, mHAQ, disability, use of methotrexate and year of initiation.
↵† Adjusted for duration of RA, baseline disease activity, age, mHAQ, disability, use of methotrexate and year of initiation.
ADA, adalimumab; CDAI, clinical disease activity index; DAS28, disease activity score employing 28-joint count; ETA, etanercept; INF, infliximab; mACR, modified American College of Rheumatology.